SF 2102 allows public school district employees and elected officials who are not covered by collective bargaining agreements for health insurance (defined as "nonstate public employees") to enroll in Iowa’s state health insurance plan. School districts must apply for this coverage, pay monthly premiums matching rates for state employees plus administrative fees, and deposit payments into a new trust fund. Unpaid premiums incur interest, and the state may withhold other district funds until payments are made. The bill requires annual reports on coverage costs and enrollment, effective July 1, 2027.
HF 2094 requires Iowa's Department of Health and Human Services to at least double the number of inpatient psychiatric beds at each state mental health institute by July 1, 2027, using the bed count from June 30, 2025, as the baseline. The bill also mandates that the department apply for a federal Medicaid waiver by October 1, 2026, to allow Medicaid funding for these additional beds. This policy directly affects Iowa's state mental health institutes by requiring them to expand capacity and navigate federal funding changes. The bill aims to increase access to inpatient psychiatric care through concrete, time-bound requirements.
This bill requires Iowa blood banks and hospitals to honor patient requests for autologous (blood donated for their own future use) or directed (blood donated for a specific person) blood donations when ordered by a physician for a medical procedure that may need transfusion. It mandates that facilities comply with these requests, subject to all existing federal and state blood donation laws, and allows them to charge a reasonable fee for facilitating such donations. The bill directly affects patients planning surgeries or procedures requiring potential blood transfusions, as well as blood banks and hospitals that handle blood donations. Key provisions clarify definitions of donation types and establish the compliance and fee rules.
HF 2056 requires Iowa's public health department to establish a standing order allowing pharmacists to dispense hydroxychloroquine and ivermectin to patients aged 18 or older upon direct request, without a prescription. Pharmacists must provide manufacturer instructions but cannot require a prescription, appointment, or record the patient encounter. The bill grants immunity from civil or criminal liability to pharmacists and the health department medical director for dispensing under this order. It directly affects patients seeking these medications and pharmacists who dispense them under the new protocol.
This bill proposes adding a new section to Iowa's Constitution protecting an individual's right to refuse any medical procedure, treatment, vaccine, or preventive care without interference. It specifically states that public accommodations (like businesses or services) cannot deny equal access or liberty based on someone exercising this right to refuse medical care. If passed, the amendment would require voter approval after being referred to the next state legislature. The change would directly affect all Iowans regarding their medical choices and how public spaces may interact with those choices.
HF 2033 requires pharmacies in Iowa to provide free accessible prescription information (including labels, bag tags, and medical guides) in formats like braille or audio to people who are blind, visually impaired, or have other print disabilities. Pharmacies must offer this directly or refer patients to an accessible location within a reasonable distance, with information provided in a timely manner comparable to non-disabled patients. Health insurers must reimburse pharmacies through an enhanced dispensing fee, and the pharmacy board must publish an annual list of compliant pharmacies online. The law excludes institutional pharmacies (e.g., hospital pharmacies) and certain correctional or donation-based settings, with rules to be adopted by January 1, 2027, and a progress report due by January 2028.
This bill requires manufacturers of mRNA and DNA-based vaccines to conduct safety studies on transmissibility, DNA contamination, and shedding before distributing them in Iowa. Distributors who provide vaccines posing unreasonable public health risks (as defined by the FDA) face $1,000 fines per violation and potential licensing penalties. It also removes liability immunity for manufacturers if a vaccine’s design defect causes injury or death. The Department of Inspections must create enforcement rules under this law. The bill directly affects vaccine manufacturers, distributors, and healthcare providers handling these vaccines within Iowa.
HF 2249 establishes new rules for vision benefit managers in Iowa, directly affecting optometrists and vision care providers who contract with these plans. The bill requires that reimbursement rates for covered vision services must be at least the Medicare physician fee schedule for those services, updated annually for inflation. It also mandates that the time frame for vision benefit managers to recover payments from providers (chargebacks) must match the time they have to pay providers, and prohibits managers from favoring providers based on discounts, volume, or brand. These provisions aim to create fairer payment practices and greater transparency in vision care billing.
SF 2014, the "Restroom Emergency Access Act," requires retail businesses to allow customers with qualifying medical conditions emergency access to employee restrooms during business hours under specific conditions. It defines "eligible medical conditions" to include inflammatory bowel diseases, irritable bowel syndrome, ostomy device users, and other conditions needing immediate restroom access, requiring written documentation from a healthcare provider. Businesses must permit access if public restrooms are unavailable, sufficient staff are present, and the restroom area is safe - without requiring physical changes to the restroom. Violations incur a $200 civil penalty for repeat offenses, with businesses immune from liability unless grossly negligent.
HF 2009 defines key terms related to 340B drugs (prescription drugs sold at reduced prices under federal law) and prohibits drug manufacturers or distributors from interfering with covered entities (like hospitals or clinics) acquiring these drugs or delivering them to contract pharmacies. It specifically bans manufacturers or distributors from denying, restricting, or hindering this process unless federal health authorities have already prohibited it. The bill directly affects healthcare providers using 340B pricing and the pharmacies that serve them. It ensures that state-level rules align with federal 340B program requirements by preventing unnecessary barriers to accessing these discounted drugs.
